Fresenius Settles With Johnson & Johnson to Market Stelara Alternative
By David Sachs
Pharmaceutical companies Fresenius Kabi and Formycon have reached a settlement with Johnson & Johnson to commercialize a Crohn's Disease drug in Europe and Canada.
Fresenius said Monday that the terms of the settlement for the drug, which mirrors Johnson & Johnson's trademarked Stelara, are confidential. Known as FYB202, the treatment also aids people with plaque psoriasis and ulcerative colitis, and is awaiting approval from regulators.
The settlement follows a similar one with Johnson & Johnson in the U.S. context. Fresenius Kabi and Formycon have had a license agreement in place since last year for marketing the drug after its approval, Fresenius said.
Johnson & Johnson did not immediately respond to a request for comment.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
March 18, 2024 05:51 ET (09:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
5 Stocks to Buy While They’re Trading at Big Discounts
-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
After Earnings, Is Uber Stock a Buy, a Sell, or Fairly Valued?
-
Lowe’s Earnings: Tumultuous Macro Weighs on Near-Term Results but Fails to Sway Our Long-Term View
-
Macy’s Earnings: Plan Taking Shape Despite Tough Environment
-
JPMorgan Investor Day: CEO Dimon Pushes Against More Stock Buybacks at Current Prices
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
3 Cheap and Dependable Dividend-Growth Stocks to Buy
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?